D306e740 28b8 4975 Acd3 5261dc07ed47 01
Abacavir And Lamivudine Tablet, Film Coated
Product Images NDC 69097-362
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Abacavir And Lamivudine (NDC 69097-362). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
D306e740 28b8 4975 Acd3 5261dc07ed47 02
D306e740 28b8 4975 Acd3 5261dc07ed47 03
This is a description for Abacavir and Lamivudine tablets, USP which come in a 600 mg/300 mg dosage. The package contains 90 tablets. The text also includes instructions for authorized dispenser related to patient information, warning signs, and dosages. The tablets have been manufactured by Cipla USA. The rest of the text is not understandable due to scanning errors and inaccuracies.*
D306e740 28b8 4975 Acd3 5261dc07ed47 04
The text is a description of Abacavir and Lamivudine Tablets, USP used for the treatment of patients with HIV-1 infection. Each tablet contains Abacavir Sulfate USP equivalent to Abacavir 600 mg and Lamivudine USP 300 mg. The recommended dosage is given in the prescribing information. They are manufactured by Cipla Ltd. in India and distributed by Cipla USA, Inc. in Florida, USA. They need to be stored at a controlled room temperature between 15°C to 30°C (59°F to 86°F), and kept out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
